Amniotic fluid stem cell therapy improves erectile function in a diabetic rat model.

Area of Science:

• Regenerative Medicine
• Stem Cell Therapy
• Urology

Background:

• Diabetic erectile dysfunction (ED) involves neural, vascular, and smooth muscle degeneration.
• Current ED treatments offer symptomatic relief but don't address underlying causes.
• Amniotic fluid-derived stem cells (AFSCs) show potential for tissue regeneration.

Purpose of the Study:

• Evaluate AFSCs for treating diabetic ED in a rat model.
• Assess AFSCs' impact on erectile function and penile tissue regeneration.
• Investigate AFSCs' therapeutic potential for neurovascular repair and senescence reduction.

Main Methods:

• Diabetic ED induced in Sprague-Dawley rats using streptozotocin.
• Intracavernous injection of AFSCs (1 × 10^6 cells/rat).
• Evaluated erectile function, penile histology, and cellular senescence via specific markers and staining.

Main Results:

• AFSC treatment significantly improved erectile function (increased intracavernous pressure/mean arterial pressure ratio).
• Restored neuronal and endothelial markers, increased smooth muscle actin expression.
• Reduced cellular senescence (β-galactosidase activity) in penile tissues.

Conclusions:

• Intracavernous AFSC therapy effectively restores erectile function in diabetic rats.
• AFSCs promote neurovascular regeneration and reduce penile tissue senescence.
• AFSCs represent a promising regenerative approach for diabetic ED, warranting further research.